Balloon Pulmonary Angioplasty in Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.039002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Takatoyo Kiko und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Circulation, Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Osaka Japan. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Ubiquitin-Protein Ligases, Pulmonary Embolism, Hypertension, Pulmonary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The heterozygous ring finger protein 213 (RNF213) p.Arg4810Lys variant has been identified in patients with chronic thromboembolic pulmonary hypertension (CTEPH). This study aimed to clarify the influence of the RNF213 p.Arg4810Lys variant on the response to balloon pulmonary angioplasty (BPA) in patients with CTEPH.
Methods
We retrospectively analyzed 93 patients with CTEPH who underwent BPA by analyzing the RNF213 p.Arg4810Lys variant. Clinical parameters and hemodynamics following BPA were compared between RNF213 p.Arg4810Lys variant carriers and noncarriers, along with BPA‐related complications.
Results
Among 93 patients, 7 (8%) were heterozygous RNF213 p.Arg4810Lys variant carriers and 86 (92%) were noncarriers. Both groups showed significant improvements in mean pulmonary artery pressure and pulmonary vascular resistance following BPA. However, the 6‐minute walk distance, symptoms, cardiac index, and right ventricular function did not significantly improve in heterozygous RNF213 variant carriers, whereas noncarriers showed notable improvements. Group differences in mean change from baseline to follow‐up were significant in cardiac index (0.4 L/min per m 2 [95% CI, 0.1–0.8]; P =0.019), 6‐minute walk distance (70 m [95% CI, 6–135]; P =0.036), and right ventricular ejection fraction (9% [95% CI, 5–12]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary Circulation, Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Osaka Japan.
- Department of Vascular Physiology National Cerebral and Cardiovascular Center Research Institute Osaka Japan.
- Department of Radiology National Cerebral and Cardiovascular Center Osaka Japan.
ORCID-Profile: Ryotaro Asano, Tomohiko Ishibashi, Shinya Fujisaki, Naruhiro Nishi, Hiroya Hayashi, Hiroki Horinouchi, Jin Ueda, Akihiro Tsuji, Tetsuya Fukuda, Yoshikazu Nakaoka, Takeshi Ogo
Zitieren
APA
Kiko, T., Asano, R., Ishibashi, T., Endo, H., Fujisaki, S., Takano, R., Akao, M., Nishi, N., Hayashi, H., Kotoku, A., Horinouchi, H., Ueda, J., Tsuji, A., Fukuda, T., Nakaoka, Y., & Ogo, T. (2025). Balloon Pulmonary Angioplasty in Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039002
Vancouver
Kiko T, Asano R, Ishibashi T, Endo H, Fujisaki S, Takano R, et al. Balloon Pulmonary Angioplasty in Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039002
BibTeX
@article{Kiko2025,
author = {Kiko, Takatoyo and Asano, Ryotaro and Ishibashi, Tomohiko and Endo, Hiroyuki and Fujisaki, Shinya and Takano, Ryo and Akao, Mitsumasa and Nishi, Naruhiro and Hayashi, Hiroya and Kotoku, Akiyuki and Horinouchi, Hiroki and Ueda, Jin and Tsuji, Akihiro and Fukuda, Tetsuya and Nakaoka, Yoshikazu and Ogo, Takeshi},
title = {Balloon Pulmonary Angioplasty in Heterozygous RNF213 p.Arg4810Lys Variant Carriers Diagnosed With Chronic Thromboembolic Pulmonary Hypertension},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039002}
}
EUVIMED